Indian Clinical Experience on Innovative Product in Treatment of Male Infertility

ABSTRACT
Rising number of infertile males in India provokes the need of evidence-based comprehensive formula addressing unattended causes of male infertility. There is an innovative product*, a combikit available in Indian market, containing 30 tablets of antioxidant, multivitamin, amino acid and mineral tablets, with documented evidence on ingredients in treatment of male infertility, and 25 tablets of clomiphene citrate which is a time-tested drug in treatment of male infertility (in particular oligospermia and/or asthenospermia). In order to assess efficacy of the product in Indian infertile male patients, we undertook phase IV multicentric clinical study, at 18 centers across India in 100 patients.

Very high couple pregnancy rate of 53% was reported. As first line treatment of male infertility (in particular oligospermia and/or asthenospermia), the use of this innovative product therefore holds a strong promise.

Keywords: Male infertility, Combikit, Couple pregnancy rate.

INTRODUCTION
Male infertility is rising phenomenally in India. Although products are available, it is observed that hyperhomocysteinemia, oxidative stress, amino acid and mineral deficiency which are the independent causative factors for male infertility1-3,13 are not being addressed by one comprehensive product in the routine management of male infertility.

There is an innovative product available in Indian market, launched for the first time in the year 2009. The product is a combikit containing 30 tablets of fixed dose combination of antioxidants, multivitamin, amino acid and mineral (each tablet containing zinc sulphate—66 mg, folic acid—5 mg, methylcobalamin—1500 µg, pyridoxine—1.5 mg, coenzyme Q₁₀—60 mg, Lycopene—4 mg, selenium—200 µg, L-carnitine tartarate—50 mg, L-arginine—20 mg), with documented evidence on ingredients in treatment of male infertility and 25 tablets of clomiphene citrate (25 mg) which is a time tested drug in treatment of male infertility (in particular oligospermia and/or asthenospermia). To assess efficacy of this product in Indian male infertile patients, a multicentric study was planned.

MATERIALS AND METHODS
This was a phase IV, multicentric clinical study carried out at 18 centers across India. The cities included in the study were Mumbai, Pune, Nagpur, Kolkata, Ahmedabad, Midnapur (West Bengal), Gangtok, Indore, Ankleshwar (Gujarat), Allahabad, Kondagaon (Chhattisgarh), Jaunpur (UP), Dombivali (Maharashtra).

One hundred married men with oligospermia (sperm count less than 20 million/ml of semen but above 1 million/ml after Percoll centrifugation; gradient 40/90) and/or asthenospermia with sperm motility less than 50% progressive or less than 25% rapidly progressive were enrolled in the study and all of them completed the study.

The exclusion criteria were as follows:
• Greater than 20% antibodies present on the spermatozoa after processing with Percoll centrifugation.
• Greater than 50% of spermatozoa without an acrosome.
• Patients with sertoli cell-only syndrome, testicular malignancy or varicocele and those receiving chemotherapy or radiotherapy.
• Teratospermia—normal morphology found in less than 30% of spermatozoa.
• Subjects who, within 3 months before enrollment, were treated with any drugs indicated to increase sperm count or motility.

After enrollment, the baseline characteristics, like age, weight, history of infertility, were documented. Mean age of all the married men enrolled in the study was 31 years of age. 51.8% men suffered from 1 to 5 years of infertility. 48.2% men suffered from more than 5 years of infertility. The baseline characteristics of the patients are given in Table 1.

All the infertile married men enrolled in the study received study medication. Each patient had to consume two tablets, one brown colored antioxidant, multivitamin, amino acid and mineral tablet to be taken once daily and second white colored tablet of clomiphene citrate 25 mg to be taken once daily for

<table>
<thead>
<tr>
<th>Mean age (years)</th>
<th>31</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight (kg)</td>
<td>64.8</td>
</tr>
<tr>
<td>1-5 years of infertility</td>
<td>51.8%</td>
</tr>
<tr>
<td>More than 5 years of infertility</td>
<td>48.2%</td>
</tr>
</tbody>
</table>

* Productiv M
25 days followed by 5 days abstinence. The therapy was to be continued for 6 months. After baseline, the patient had to visit the clinic after completing 3 months treatment as well as 6 months treatment. During this visit, sperm count and sperm motility were documented in the case report form. The overall study design is given in Figure 1.

**DISCUSSION**

Even with newer and newer technological advances in the male infertility, evidence-based oral product which proves to be a first line treatment for management of male infertility is still the need of time. Also, it is observed that hyperhomocysteinemia, oxidative stress, amino acid and mineral deficiency which are the independent causative factors for male infertility are not being addressed by one comprehensive product in the routine management of male infertility. There is an innovative product\(^*\) which is available in Indian market since 2009. This is combikit containing 30 – antioxidants, multivitamin, amino acid and mineral tablets, with documented evidence\(^3\text{-}^{12}\) on ingredients in treatment of male infertility and 25 tablets of clomiphene citrate which is a time tested drug in treatment of male infertility (in particular oligospermia and/or asthenospermia). For a product, for treatment of male infertility, the best way to assess the efficacy is to assess the couple pregnancy rate.

In this phase, IV multicentric study carried in 100 infertile males at 18 centers across India, the reported couple pregnancy rate is 53%. This is a very high couple pregnancy rate reported during just 6 months of treatment. Data on sperm count and sperm motility on treatment were available only for eight patients. Yet, there was a good rise reported in these parameters too. Percent increase in sperm count over baseline was 125.8% and percent increase in sperm motility over baseline was reported to be 19.27%.

**CONCLUSION**

Success of male infertility treatment is best judged by the couple pregnancy rate. This phase IV multicentric study evaluated 6 months therapy of innovative product in treatment of 100 infertile males (suffering from oligospermia and/or asthenospermia). This product\(^*\) is a combikit containing 30 – antioxidants, multivitamin, amino acid and mineral tablets, (each tablet containing zinc sulphate—66 mg, folic acid—5 mg, methylcobalamin—1500 µg, pyridoxine—1.5 mg, coenzyme Q10—60 mg, lycopene—4 mg, selenium—200 µg.

---

<table>
<thead>
<tr>
<th>Males</th>
<th>Study group</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Males (N)</strong></td>
<td>100</td>
</tr>
<tr>
<td>Did the couple conceive?</td>
<td><strong>Yes N (%)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>No N (%)</strong></td>
</tr>
<tr>
<td>What duration did couple conceive after starting treatment?</td>
<td></td>
</tr>
<tr>
<td>After 1 month</td>
<td><strong>N (%)</strong></td>
</tr>
<tr>
<td>After 2 months</td>
<td><strong>N (%)</strong></td>
</tr>
<tr>
<td>After 3 months</td>
<td><strong>N (%)</strong></td>
</tr>
<tr>
<td>After 4 months</td>
<td><strong>N (%)</strong></td>
</tr>
<tr>
<td>After 5 months</td>
<td><strong>N (%)</strong></td>
</tr>
<tr>
<td>After 6 months</td>
<td><strong>N (%)</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Increase in sperm count over baseline (%)(^a)</strong></th>
<th><strong>Increase in sperm motility over baseline (%)(^a)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>125.8%</td>
<td>19.27%</td>
</tr>
</tbody>
</table>

\(^a\)N—represents number of cases; (%)—represents percent of those cases out of total population; \(^a\)Data on 8 patients; No adverse events were reported during the treatment period

* Productiv M
L-carnitine tartarate—50 mg, L-arginine—20 mg) with documented evidence14-28 on ingredients in treatment of male infertility and 25 tablets of clomiphene citrate 25 mg which is a time tested drug in treatment of male infertility. 53% couple pregnancy rate was reported with the study treatment. Data on eight patients also reported 125.8% increase in sperm count over baseline and 19.27% increase in sperm motility over baseline.

With a phenomenally high couple pregnancy rate in this study, this innovative product* available in Indian market containing 30 – antioxidants, multivitamin, amino acid and mineral tablets and 25 tablets of clomiphene citrate as a monthly therapy, holds a strong promise for being first line treatment of male infertility (in particular oligospermia and/or asthenospermia).

REFERENCES


ABOUT THE AUTHORS

Jayesh Amin
Infertility and IVF Specialist, Consultant, Boon IVF Centre, Ahmedabad, Gujarat, India

SK Mishra
Consultant, Department of Gynecology, Kharagpur Divisional Railway Hospital, Midnapur, West Bengal, India

Asit Kumar Dutta
Consultant, Obstetrician and Gynecologist, Department of Obstetrics and Gynecology, Asit Kumar Dutta Clinic, Midnapur, West Bengal, India

Kumud Kunwar
Assistant Surgeon, RNT Hospital, Kondagaon (Bastar), Chhattisgarh, India

* Productiv M
Indian Clinical Experience on Innovative Product in Treatment of Male Infertility

Veena G Shinde  
Consultant, Obstetrician and Gynecologist, Shinde’s Medicare Hospital, Andheri, Mumbai, Maharashtra, India

Archana Chauhan  
Consultant, Obstetrician and Gynecologist, Archana Chauhan Clinic Chhattisgarh, India

Shilpi Sud  
Consultant, Sud Hospital, Dhantoli, Nagpur, Maharashtra, India

Rashmi Maurya  
Priyanshu Dental and Maternity Hospital, Jaunpur, Uttar Pradesh India

Neeti Nepal  
Consultant, Gangtok, Sikkim, India

Pankaj Sarode  
Consultant, Pune, Maharashtra, India

KP Biswas  
Head, Department of Obstetrics and Gynecology; Consultant, ESIC Hospital and ODC (EZ), Kolkata, West Bengal, India

GP Muzumder  
Consultant, Haridevpur Clinic, Kolkata, West Bengal, India

Maulshri Chitrabanshi  
Sushila Devi Memorial Hospital, Jaunpur, Uttar Pradesh, India

Sushma Shibe  
Department of Obstetrics and Gynecology, Mayur Co-op Hsg Society Chincholipada, Subhash Road, Dombivli, Maharashtra, India

Ruma Shukla  
Consultant and Gynecologist, Indore, Madhya Pradesh, India

Neeraj Trivedi  
Consultant, Department of Gynecology, Nidhi Hospital, Ankleshwar Gujarat, India

Meena Dayal  
Tagore Town, Allahabad, Uttar Pradesh, India

Devendra Sortey  
Sortey Hospital, Dhantoli, Nagpur, Maharashtra, India

Sharvaree Shukla  
Biostatistician, Centre for Modeling and Simulation, University of Pune, Ganeshkhind, Pune, Maharashtra, India

Bharati Gawade (Corresponding Author)  
General Manager, Medical Services, Wanbury Ltd, Mumbai Maharashtra, India, e-mail: bhartig@wanbury.com